Rescuing the anti-HIV activity of APOBEC3G with small-molecule chaperons
用小分子伴侣挽救 APOBEC3G 的抗 HIV 活性
基本信息
- 批准号:7419495
- 负责人:
- 金额:$ 18.32万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-06-05 至 2011-05-31
- 项目状态:已结题
- 来源:
- 关键词:Acquired Immunodeficiency SyndromeAddressAffectAntiviral AgentsBindingBiochemicalBiological AssayCellsCellular AssayComplexCyclic PeptidesCytidine DeaminaseDefense MechanismsDevelopmentDiseaseDominant-Negative MutationDown-RegulationDrug Delivery SystemsEvaluationGeneticGenetic TranscriptionGenomeGoalsHIVHIV-1HealthHumanIn SituInfectionInterventionLeadLibrariesLigandsMembraneModificationMolecularMolecular ChaperonesMolecular WeightMutagenesisMutationOrganismOutcomeOutcomes ResearchPathogenicityPeptidesPharmaceutical PreparationsPhenotypePreventionPropertyProteinsRecruitment ActivityReporterReportingResearchResistanceReverse TranscriptionRoleS PhaseSchemeSeriesSingle-Stranded DNASolidSolutionsStructureStructure-Activity RelationshipSystemTherapeuticToxic effectUbiquitinationValidationVertebral columnViralViral GenesViral GenomeViral ProteinsVirionVirus DiseasesVirus ReplicationVisionbasedesigndrug resistant virusfunctional groupgenetic selectioninhibitor/antagonistmutantnovelprotein aminoacid sequenceprotein protein interactionprototypesmall moleculetoolubiquitin-protein ligase
项目摘要
DESCRIPTION (provided by applicant): In this proposal, we plan to evaluate the potential for developing an antiviral chemotherapeutic strategy based on the intrinsic defense mechanism of human cells: mutagenesis of single-stranded DNA by cytidine deaminase APOBEC3G (A3G). Human immunodeficiency virus 1 (HIV-1) counters this activity by expressing virion infectivity factor (Vif) that downregulates both the activity and stability of A3G. The essential role of Vif in viral proliferation and highly regulated function of A3G make their interaction an attractive target for the resistance-free intervention. Furthermore, a possibility of generating dominant negative HIV-1 mutants in situ through A3G-induced mutagenesis presents a unique opportunity to inactivate HIV in latently infected cells, normally inaccessible to chemotherapeutics. The proposed research is based on the hypothesis that small molecules capable of competing with the Vif for A3G will simultaneously protect the cellular factor from the antagonism displayed by Vif and reduce stability of the viral factor. The challenge of identifying de novo inhibitors of protein-protein interaction will be addressed in this proposal by exploiting the unique power of genetic selection to yield rare solutions. We believe, therefore, that experimental validation of this hypothesis presents a unique opportunity for curbing the progression of HIV infections through a natural defense mechanism in latently infected cells without the danger of evolving resistant phenotypes. We plan to accomplish the following Specific Aims in developing this approach:
Specific Aim 1: We will develop and implement a genetic selection scheme for the discovery of potent and selective antagonists of Vif-A3G interaction.
Specific Aim 2: We will confirm and characterize Vif-degrading and/or A3G-protecting activities of the selected backbone cyclic peptides using a series of biochemical and cellular assays.
Specific Aim 3: We will identify functional motifs important for the activity of the selected sequences and develop their cell-permeable derivatives.
The expected outcome of this research will be a series of specific and potent cell-permeable agents capable of protecting A3G from the downregulation by Vif. Our long-term objective is to advance a prototype of a new class of anti-HIV drugs that can address the three existing problems associated with the current strategies: toxicity, resistance and latency. To protect organism against viral infections, human cells have developed a sophisticated defense mechanism involving modifications of viral genes, lethal to virus replication. Unfortunately, human immunodeficiency virus (HIV) is able to counteract this intrinsic protective system making the disease that it causes, Acquired Immunodeficiency Syndrome (AIDS), a global health problem, with no cure or prevention in sight. We propose to develop a novel anti-HIV therapeutic strategy that will rescue the natural antiviral mechanism without the danger of producing drug-resistant viruses.
描述(由申请人提供):在本提案中,我们计划评估开发基于人类细胞内在防御机制的抗病毒化疗策略的潜力:胞苷脱氨酶APOBEC3G (A3G)诱变单链DNA。人类免疫缺陷病毒1 (HIV-1)通过表达下调A3G活性和稳定性的病毒粒子感染因子(Vif)来对抗这种活性。Vif在病毒增殖中的重要作用和A3G的高度调控功能使它们的相互作用成为无耐药性干预的一个有吸引力的靶点。此外,通过a3g诱导的诱变在原位产生显性阴性HIV-1突变体的可能性提供了一个独特的机会来灭活潜伏感染细胞中的HIV,这些细胞通常是化疗药物无法进入的。提出的研究基于这样的假设,即能够与Vif竞争A3G的小分子将同时保护细胞因子免受Vif所表现出的拮抗作用,并降低病毒因子的稳定性。鉴定蛋白质-蛋白质相互作用的新生抑制剂的挑战将在本提案中通过利用遗传选择的独特力量来产生罕见的解决方案来解决。因此,我们相信,这一假设的实验验证提供了一个独特的机会,可以通过潜伏感染细胞中的自然防御机制来抑制HIV感染的进展,而不会产生抗性表型的危险。我们计划在制定这一方法时实现以下具体目标:
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Sergey N. Savinov其他文献
Sergey N. Savinov的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Sergey N. Savinov', 18)}}的其他基金
Rescuing the anti-HIV activity of APOBEC3G with small-molecule chaperons
用小分子伴侣挽救 APOBEC3G 的抗 HIV 活性
- 批准号:
7858536 - 财政年份:2009
- 资助金额:
$ 18.32万 - 项目类别:
Targeting A-beta with evolved site-specific proteases
使用进化的位点特异性蛋白酶靶向 A-β
- 批准号:
7361795 - 财政年份:2008
- 资助金额:
$ 18.32万 - 项目类别:
Targeting A-beta with evolved site-specific proteases
使用进化的位点特异性蛋白酶靶向 A-β
- 批准号:
7565916 - 财政年份:2008
- 资助金额:
$ 18.32万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 18.32万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 18.32万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 18.32万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 18.32万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 18.32万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 18.32万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 18.32万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 18.32万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 18.32万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 18.32万 - 项目类别:
Research Grant